Albuquerque, New Mexico – August 17, 2015 – Intellicyt, the leading provider of innovative, high-throughput, high-content cell and bead-based screening solutions today announced its latest TAP awardee and partner, Dr. G. Reid Asbury, CEO of SpectraGenetics, Inc. The Intellicyt TAP Program was created to collaborate with pioneering scientists and commercial partners to advance the frontier of cell- and bead-based assays, and discover new therapeutic leads through the use of our proprietary High Throughput Flow technology.
“We’re delighted to welcome SpectraGenetics as the newest member of the TAP program.” stated R. Terry Dunlay, CEO of Intellicyt. Dr. Asbury’s use of the Intellicyt’s iQue® Screener instrument and ForeCyt® software will further the development of a new type of internalization and trafficking assay for G-Protein Coupled Receptors (GPCR’s), an important class of proteins for therapeutic development. The combination of this assay with the Intellicyt iQue Screener’s ability to measure 50,000 wells per day in 96-, 384- or 1536-well microplates, will enable assessment of very large (1,000,000+) primary compound screens.
“The iQue Screener in combination with Spectragenetics’ GPCR screening reagents, is the perfect solution, offering unrivaled data quality and throughput for this valuable class of drug targets,” Dr. Asbury stated.
Research institutions or companies interested in participating in the Intellicyt TAP Program are invited to visit our website for additional details on the TAP Program application process.
Intellicyt produces innovative tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. This information is used to revolutionize the discovery and development of new drugs and to provide new insight into the diagnosis of diseases. Intellicyt was the first to commercialize a true high throughput, cell-based screening platform optimized for suspension cells and multiplex beads. Intellicyt’s instrumentation, software, and reagent products are used worldwide throughout pharmaceutical, biotechnology, and life science research organizations.
SpectraGenetics is an innovative gene tagging company providing proprietary and breakthrough technologies for drug discovery and development. SpectraGenetics’ lead products based on fluorogen activating peptide (FAP) technology allow for high throughput, direct measurement of GPCR internalization and trafficking. These GPCR assays are used by many leading pharmaceutical, biotechnology and life science research institutions worldwide.
All product and service names mentioned are the trademarks of their respective companies.
Click here to contact Intellicyt.